Detalhe da pesquisa
1.
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors.
Haematologica
; 108(4): 1092-1104, 2023 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36519324
2.
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.
Hematol Oncol
; 40(1): 22-30, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34713465
3.
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
BMC Cancer
; 18(1): 466, 2018 04 25.
Artigo
Inglês
| MEDLINE | ID: mdl-29695239
4.
Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL.
Blood
; 135(22): 2000-2004, 2020 05 28.
Artigo
Inglês
| MEDLINE | ID: mdl-32181815
5.
Clonal hematopoiesis of indeterminate potential in persons with HIV.
AIDS
; 38(4): 487-495, 2024 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37976039
6.
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.
Haematologica
; 103(11): e541-e543, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-29794145
7.
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma.
Cancer Rep (Hoboken)
; 5(7): e1524, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34319003
8.
Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3.
Hemasphere
; 5(1): e510, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-33364550
9.
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Lancet Haematol
; 5(3): e109-e116, 2018 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-29396091